Paccal Vet Hemangiosarcoma Trial
Now enrolling: A clinical study for dogs with splenic hemangiosarcoma
Fully funded study, no cost to pet owner
No placebo, all dogs receive active treatment
Paccal Vet is based on a cancer drug widely used in human medicine
What is hemangiosarcoma?
Hemangiosarcoma is an aggressive and often deadly cancer in dogs. It spreads quickly through the body, and once it has metastasized (spread to other organs), it is very difficult to treat. Currently, there are no FDA-approved treatments for hemangiosarcoma in dogs.
The standard treatment involves surgery to remove the tumor, often followed by chemotherapy with a drug called doxorubicin. However, its beneficial effects are limited, with most dogs surviving just a few months after diagnosis.
Exploring new forms of chemotherapy that have not previously been available or safe for use in dogs may contribute to expanding treatment options for dogs diagnosed with this devastating disease.
Why is this study being done?
We are studying Paccal Vet as a possible new treatment option for dogs with splenic hemangiosarcoma.
Paccal Vet is a chemotherapy that has been specifically designed for pets, and it is based on a cancer drug that is widely used and approved in human cancer care.
Paccal Vet has been used in clinical studies to treat over 300 dogs with cancer. It has shown promising results in treating certain dog cancers, including mast cell tumors, squamous cell carcinoma, and mammary cancer.
The purpose of this study is to test the tolerability of Paccal Vet and to see whether it may improve survival in dogs with hemangiosarcoma of the spleen.
Why participate?
Give your dog access to a promising investigational drug based on a widely used and approved drug in human cancer care
Benefit from regular medical check-ups and close monitoring throughout the study
Contribute to advancing research for hemangiosarcoma, an aggressive cancer with no approved treatments
What to Expect
The study has three parts: a screening phase, a treatment phase, and follow-up care after the treatment phase completed.
All patients will receive Paccal Vet once every 3 weeks for a total of 4 doses.
Your dog will be closely monitored with health check-ups, blood tests, scans, and quality of life surveys. This approach ensures close monitoring of your dog’s health and wellbeing and to see how the treatment is working.
The study consists of around 10-12 study visits over 1 year.
All dogs in this study will receive Paccal Vet. There is no placebo group in this study, therefore, if your dog is enrolled, he or she will be receiving the study drug.
Participating hospitals
BluePearl Kirkland, Kirkland, WA
BluePearl Tacoma, Lakewood, WA
Bridge Animal Referral Center, Edmonds, WA
Colorado Animal Specialty and Emergency, Boulder, CO
Pacific Northwest Pet Emergency and Specialty Center, Vancouver, WA
VCA Northwest Veterinary Specialists, Clackamas, OR
Veterinary Referral Center of Central Oregon, Bend, OR
Veterinary Specialty Hospital - North County, San Marcos, CA
Take survey to see if you may qualify
Study management
CASTR Alliance was founded in 2019 by veterinary clinician-scientists Jessica Bertout and Jim Perry. As scientists, they bring extensive experience in designing, managing, and conducting clinical trials that meet the rigorous standards of the biotech industry. Moreover, as devoted pet owners and veterinarians, they are personally committed to delivering the highest quality care for our animal companions. Together, Drs. Bertout and Perry created CASTR Alliance to leverage their expertise and advance medicine for humans and animals alike.
Study sponsor
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are unmet medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet, which is being developed for the treatment of cancer in dogs and cats.